Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.

University researchers will examine adenosine receptor modulator technology’s potential in C. difficile infection and atherosclerosis. CRISPR Therapeutics is partnering with University of Alabama-Birmingham to evaluate gene-editing procedures in Friedreich’s ataxia.

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in March and April 2017.

Believing biomedical research at Duke is “under fished” compared to the ponds in San Francisco and Boston, Duke’s institutional CRO looks to provide clinical trial design and other services to help tech transfer along. Plus, recent tech transfer deals include AbbVie, Calimmune and China’s Yisheng.